StemCell Therapy

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors alone or in combination with basal insulin is a safe and an effective treatment option for hospitalized patients with type 2 diabetes, according to the results of a post hoc analysis published in Endocrine Practice.

Insulin is the recommended treatment regimen for hyperglycemia in hospitalized patients with type 2 diabetes and hospital use of oral antidiabetic agents has not been recommended because there are limited data from randomized controlled trials. Researchers completed a post hoc analysis of pooled data from 3 randomized clinical trials to determine the efficacy and safety of DPP-4 inhibitors alone or in combination with basal insulin compared with a basal-bolus insulin regimen in general medicine and surgery patients with type 2 diabetes.

The Sita-Pilot, Sita-Hospital, and Linagliptin-Surgery studies included patients with type 2 diabetes aged 18 to 80 years who were expected to stay in hospital for >24 hours and had blood glucose levels between 140 and 400 mg/dL prior to random treatment assignment. Sitagliptin once daily, alone or in combination with basal insulin, was used in the Sita-Pilot and the Sita-Hospital studies, whereas linagliptin alone was used in the Linagliptin-Surgery study.

In total, 144 patients received a DPP-4 inhibitor alone, 158 received a DPP-4 inhibitor plus basal insulin, and 283 received a basal-bolus regimen. The primary outcome was to determine differences in mean daily blood glucose concentrations between the groups. All groups received correctional doses of rapid-acting insulin for blood glucose levels >140 mg/dL.

The pooled data from the 3 prospective clinical trials showed that hospital treatment with DPP-4 inhibitors alone or in combination with basal insulin resulted in a similar improvement in mean daily blood glucose concentration compared with a basal-bolus regimen (17139 mg/dL, 17142 mg/dL, and 17245 mg/dL, respectively; P =.94). The percentage of patients achieving blood glucose levels within the target range of 70 to 180 mg/dL also did not differ between the groups (63%32%, 60%31%, and 64%28%, respectively; P =.42).

Patients treated with DPP-4 inhibitors alone had fewer hypoglycemic events compared with those treated with DPP-4 inhibitors plus basal insulin or basal-bolus insulin (2%, 9%, and 10%, respectively; P =.004).

Median length of stay was similar with the 3 treatment regimens and was 4.0 days (interquartile range, 3-6 days) with DPP-4 inhibitors alone, 4.0 days (interquartile range, 3-8 days) with a combination of DPP-4 inhibitors plus insulin, and 4.0 days (interquartile range, 3-7 days) with a basal-bolus regimen (P =.12).

The study had several limitations, including the open-label design of the 3 clinical trials and the exclusion of patients admitted to an intensive care unit, those with significant kidney or liver dysfunction or severe hyperglycemia, and those who received a high insulin dose.

[T]his post-hoc analysis supports the use of [DPP-4 inhibitors], alone or in combination with basal insulin in hospitalized patients with [type 2 diabetes] who were treated at home with diet, any combination of oral antidiabetic drugs, or with low-dose insulin therapy, concluded the researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @EndoAdvisor

Reference

Lorenzo-Gonzlez C, Atienza-Snchez E, Reyes-Umpierrez D, et al. Safety and efficacy of DPP4-inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes [published online April 27, 2020]. Endocr Pract. doi:10.4158/EP-2019-0481

Originally posted here:
The Role of DPP-4 Inhibitors in Hospitalized Patients With Type 2 Diabetes - Endocrinology Advisor

My physicians support my low-carb lifestyle and, honestly, they are impressed with my tight control in less than a year out from my diagnosis, Alli tells Yahoo Life. (Photo courtesy of LowCarbDiabetic)

Receiving a diagnosis of diabetes can be shocking under ordinary circumstances. For Alli, the woman behind the popular Instagram account LowCarbDiabetic, the prognosis came right before she started medical school.

Im a career changer, and had some routine lab work done before leaving for medical school, Alli, tells Yahoo Life. My lab results showed dangerously high glucose levels. Glucose, aka sugar, is your bodys main source of energy, MedlinePlus explains. High glucose levels can be a sign of diabetes.

My doctor and I thought it might be an error because Ive been a runner and health nut for years, Alli says. But, after she did another glucose test, the diagnosis was official: She had diabetes.

It was a shocking diagnosis, but [it] made sense looking back at how Id been feeling over the last year, says Alli. She originally thought the fatigue she experienced and the fact that she was running slower than usual were due to school burnout. Alli also didnt pay a lot of attention to classic signs of diabetes, like having an increased appetite without gaining weight and being thirstier than usual.

Having diabetes is not for the faint-hearted, Alli says. If youre going to have good control, you have to find your inner warrior, she adds.

Alli now takes between four to six insulin injections a day and is very strict with her diet. She was already on a fairly low-carb diet at the time of her diagnosis, and shes maintained that.

But Alli admits she was confused when her doctor handed her a pamphlet from the American Diabetes Association (ADA) after her diagnosis that recommended she eat carbohydrates. It called for eating more carbs than I had in years.

Alli still gets carbs from fruits and vegetables, but shes cut out things like bread, rice, pasta and potatoes. Along with running regularly, she says that sticking to a low-carb diet has helped her reduce her insulin doses and helps keep her glucose levels within her target range.

Currently the ADA, notes on its website that eating too many carbs can raise your blood glucose too high. However, the organization adds, Eating too little carbohydrates can also be harmful because your blood glucose may drop too low, especially if you take medicines to help manage your blood sugar.

The ADA specifically recommends that patients with diabetes get their carbohydrates the most from whole, unprocessed, non-starchy vegetables like broccoli, tomatoes and green beans, and less from refined, highly-processed carbohydrate foods and foods with added sugar, like soda, white bread and cake. The ADA advises that minimally-processed carbs like brown rice, whole wheat bread, whole grain pasta and oatmeal are also OK.

While a low-carb diet may work for some patients with diabetes, its hard to say that its the right fit for all diabetic patients, according to Katherine Araque, MD, an endocrinologist and director of endocrinology of the Pacific Neuroscience Institute at Providence Saint Johns Health Center in Santa Monica, Calif. Its not one size fits all, says Araque.

Leigh Tracy, RD, a dietitian and diabetes educator at The Center for Endocrinology at Mercy Medical Center in Baltimore, agrees, telling Yahoo Life, that diabetics dont need to swear off carbs if they dont want to. Carbohydrates are not bad. They actually give your body necessary energy, she explains.

My physicians support my low-carb lifestyle and, honestly, they are impressed with my tight control in less than a year out from my diagnosis, she says.

After sharing her low-carb recipes with friends and family, Alli eventually decided to create an ebook of her recipes, called Beginners Guide for Low Carb Recipes.Its a lifestyle.

Despite her controlled diabetes, Alli says her condition is always on my mind. I just have to deal with it, she says. There are people with much more severe illnesses. I got a bad deal, but its really not that bad at the end of the day. Ive taken as much control as I can.

More

Read more:
The controversial diet that helped one woman control her diabetes - Yahoo Lifestyle

For some diabetics, keeping blood sugar at the right level means several injections a day, every day. Injecting insulin is no fun, but for type 1 diabetics, it's the difference between life and death. Could technology be poised to offer a way to take some of the pain and stress out of managing diabetes?

People with type 1 diabetes don't make a hormone called insulin, which lets glucose into the blood to enter cells and gives the body energy. Instead of using the insulin made by their pancreas, type 1 diabetics get their insulin by regularly injecting it themselves. Apart from the pain of the needle, injections can cause the skin to get irritated, and over time it can shrink or thicken up. Get the dose wrong, and a type 1 diabetic can end up seeing their blood sugar plunge to the extent that they need to be hospitalised.

Could an end to the constant injections be in sight? Researchers have been exploring whether swapping one big needle for lots of tiny ones could help.

SEE: 60 ways to get the most value from your big data initiatives (free PDF)

"For people who are using insulin... the treatment is done as a subcutaneous injection. It's a daily injection that can be quite painful, and also not convenient," says Zhen Gu, professor in UCLA's department of bioengineering.

Gu and his team are working on a wearable patch that can pass insulin through the skin. The patch is made up of a suite of insulin-carrying microneedles. The microneedles, just 800 micrometers long, are composed of a polymer matrix of an enzyme called phenylboronic acid (PBA). They sit just under the top layer of the skin, and react to changes in blood sugar. When the patch's wearer starts to get high blood sugar, a reaction takes place that alters the electric charge of the PBA molecules, causing the microneedles to swell and release insulin into the skin. Once the glucose has dropped back to normal levels, the needles stop releasing the insulin.

The patch would be around the size of a quarter (around two-and-a-half centimetres), and would either be replaced every day, or two or three times a day, in line with how often the wearer would typically take their insulin injection. The system is painless, according to Gu, "and it can enhance people's quality of life".

Other research efforts are also looking into the potential of microneedles for insulin delivery. MIT and pharma company Novo Nordiskhave developed a pill for insulin. Normally, insulin can't be taken as a tablet because it would be broken down by the highly acidic stomach environment before it can be taken up into the blood. In the MIT system, once the pill reaches the small intestine, the outer casing breaks down and dissolvable microneedles anchor it to the gut wall to deliver the insulin.

Patches and pills still rely on the user to take their insulin at the right time, and make sure they have the right amount of insulin to hand when it's time to take it. Medical device companies are hoping to overcome the problem by taking the user out of the equation altogether with 'artificial pancreas' systems.

The artificial pancreas, also known as 'closed loop' insulin delivery systems, are worn on the body continuously. A tiny plastic tube that sits under the skin samples the glucose level in the interstitial fluid, the liquid that surrounds the body cells. The glucose monitor relays the user's blood sugar level to the pump, and it changes the amount of insulin it dispenses to keep the wearer's blood sugar in the right range.

Most systems available at present are known as 'hybrid' closed loop systems. Such systems deliver the 'basal' or background level of insulin. However, the user has to feed additional information on their meals and manual blood-glucose readings into the system in order to get 'bolus' doses the quick shots of rapid-acting insulin taken around meals. Insulin pump hardware companies are working on full closed loop systems that can automatically deliver both basal and bolus doses without the need for human intervention.

According to James Hayward, IDTechEx's principal technology analyst, the question about how big the difference is between hybrid closed loop and full closed loop is still out there. The full closed loop system including bolus doses would be the ultimate ideal he says, because then it's a full artificial pancreas approach: "But in practice, you're still pretty close with the hybrid closed loop. I don't think it's even so much a specific hardware or technology change [from one to the other]. It's just a case of getting the algorithms efficient enough and the sensor responsive enough."

SEE: Blood, sweat, tears and big data: The new wave of innovation in managing diabetes

While the full-on artificial pancreas may be a few years away from commercial distribution, the market for hybrid devices is still likely to increase.

"Do I see the insulin pump market growing? Yes, I do, absolutely," says Siddharth Shah, program manager in Frost and Sullivan's transformational health practice. But Shah points to the costs, which can climb to as much as $7,000: "For one person, that's almost an impossible cost to bear on their own completely."

It's a problem the makers appear to have recognised and have struck up new ways of billing to address the high cost. Rather than just striking deals for a given number of units, deals between hardware vendors and insurers such as the agreement between UnitedHealthcare and Medtronic focused instead on the health outcomes. According to the two companies, patients using the closed loop systems had 27% fewer hospital admissions that those without.

There are signs in the wider healthcare world that the closed loop systems are better at keeping blood sugar under control than manual alternatives:one study in the New England Journal of Medicinefound that type 1 diabetics with closed loop systems spent a lot more time in the normal blood sugar range than those getting their insulin solely through injections.

Another factor that may help boost take-up is an increasing move towards interoperability. Companies such asTidepoolare offering software to manage closed loop systems that include glucose monitors and insulin pumps from different manufacturers, so users of closed loop systems can now pick the exact mix of sensor, pump, and controller software that suits them best. As well as handling glucose delivery, such apps can also allow users to feed in data on their lifestyle, food, and other events to learn about managing their blood sugar better. "The entire industry ideally needs to move towards the data-driven approach," says Shah.

Go here to see the original:
Diabetes management: How researchers are looking at new approaches from insulin patches to an artificial pancreas - ZDNet

MAY 10, 2020 -- The story of COVID-19 and the science behind the pandemic is evolving rapidly every day, with a flurry of publications in various clinical and preclinical journals.

Here, I summarize the known and unknown links between diabetes and COVID-19, focusing on three pertinent clinical questions.

How does diabetes affect the risk for COVID-19 infection?

Just as with other respiratory illnesses, such as influenzaA, it appears that diabetes increases the risk for COVID-19 infection, although no prevalence studies comparing people with and without diabetes for COVID-19 have been published to support this presumption.

Several studies from China, Italy, and the United States suggest that diabetes increases risks for severe COVID-19 complications and mortality. In one Chinese study, people with diabetes had the second highest fatality rate (7.3%) after cardiovascular disease (CVD; 10.5%) among those with comorbid conditions.

Although several questions regarding mechanisms responsible for increased severity of COVID-19 with diabetes need to be investigated (immune dysfunction, link to comorbidities such as hypertension or obesity, link to complications such as CVD or nephropathy), the single most important outstanding clinical question in my mind is: What is the role of achieving euglycemia in COVID-19 infection and its severity? That is, does improving glucose control (chronically in an outpatient setting or acutely in an inpatient setting) result in primary prevention of COVID-19 infection or reduce its complications and fatality?

Notably, a recent data analysis for hospitalized patients with COVID-19 suggested a much higher mortality rate and increased length of stay among those who developed hyperglycemia during their hospital stay but had no evidence of diabetes before being admitted. Similarly, a previous publication had found an independent association between fasting glucose at hospital admission and severity of H1N1.

The question that needs to be explored further in both type 1 and type 2 diabetes, however, is whether acute hyperglycemia is truly an independent causal factor or simply a marker for increased severity and mortality from COVID-19.

Additional investigations into the efficacy (or at least safety) of common diabetes medications in relation to COVID-19 infection would be of clinical interest. Specifically, ACE2 and DPP-4 have been identified as receptors for the coronavirus and a related virus. Some reassurance on the safety of ACE inhibitors and angiotensin receptor blockers with COVID-19 hospitalizations is provided by recent retrospective study publications.

Clinical pearls: Healthcare providers should continue to follow routine diabetes management guidelines and encourage their patients to follow lifestyle modifications within the bounds of lockdown, along with medication adherence. In addition, it behooves us to counsel people with diabetes about the potentially higher risk for COVID-19 severity and re-emphasize public health prevention measures such as hand hygiene, physical distancing, wearing masks, etc.

How might this pandemic affect diabetes management?

Lockdowns across the globe pose serious challenges for acute non-COVID care, with many elective procedures and surgeries being postponed.

Several newspaper reports suggest that people may be averse to seeking emergency hospital care because of worries about COVID-19 infection or about hospital capacity. Timeliness of acute care by community clinics may be affected, leading to people presenting to emergency departments later in the course of disease (eg, heart attack, stroke, diabetic ketoacidosis, hyperglycemic coma, cellulitis, gangrene).

This acute care interruption in diabetes, as depicted in the figure below (which was designed by my daughter), may recur like a shadow after each subsequent wave of COVID-19 infection anticipated over the next year.

In addition to acute care interruption, COVID-related changes in care patterns will invariably have a negative impact on the comprehensive management of diabetes, including metabolic control, self-care behaviors, and self-management (depicted in the figure as morbidity and mortality related to chronic care interruption).

The extent of these COVID-19 infection waves and their effect on acute or chronic care may vary among countries and will need to be monitored carefully by analyses of national health systems.

Clinical pearls: Mitigation strategies to lesson the damaging impact of chronic care interruption involves health systems and healthcare providers adapting to the "new normal" of reduced or nonexistent face-to-face diabetes visits by adopting virtual technologies and innovative team-based approaches for diabetes management.

Should patients with diabetes be prioritized for COVID-19 vaccine research and rollout?

Many believe that a COVID-19 vaccine is the light at the end of a long tunnel. On the basis of the possible links between COVID-19 and diabetes, perhaps people with diabetes should be among the torchbearers.

With safety trials already underway in many countries, efficacy trials should prioritize people who are at risk for severe infectionthose who are older or who have conditions such as diabetes and CVDso as to potentially expedite vaccine development timelines and to prove efficacious immunity in these highest-risk groups. When an approved vaccine is available, it might also make sense to prioritize vaccinating high-risk groups first, including essential workers.

Harpreet S. Bajaj, MD, MPH, is a community endocrinologist in Brampton, Ontario, and vice chair of the Diabetes Canada Guidelines. His clinical and research interests are the prevention and management of diabetes and its related complications. He is the founder of STOP Diabetes Foundation and volunteers with numerous community public health organizations to raise awareness of diabetes prevention and treatment.

References

2020 WebMD, LLC. All Rights Reserved.

View post:
Known and Unknown Links Between COVID-19 and Diabetes - MedicineNet

A person with Type 2 diabetes is three times more likely to break a bone than a nondiabetic. Since the number of people with diabetes is increasing rapidly in the United States, skeletal fragility in patients with Type 2 diabetes is a growing, but little-known, public health issue.

Usually poor bone density is the culprit behind fragile bones, but that is not the case with Type 2 diabetics, who tend to have normal to high bone density. Yet, they still suffer from fractures at an alarming rate. Nobody knows why.

In my Bone Biomechanics Lab, we try to understand what is going wrong by looking deep inside diabetic bone, at the micro-level. We think we are on our way to identifying one of the biological mechanisms that explains bone fragility in people with diabetes.

Bones are living organs. They give the body structure and protection; contain a living space for marrow, where blood cells are produced; and provide a steady supply of minerals, including calcium and phosphorus.

If injured, bones can repair themselves on their own or with medical intervention, as anyone who has ever broken a bone can attest. But what you might not know is that bones are in a continuous state of repair through a process called remodeling.

Every day, physical activity causes wear and tear on bones in the form of micro-fractures, which the body routinely repairs. The bone healing process involves breaking down the minerals and proteins in worn-out regions and replacing them with healthy new proteins.

These fresh proteins are made up of amino acids, which naturally react with sugars in the body. Think of how a sliced apple gradually browns when exposed to air. The chemical reaction between amino acids and sugar inside the body is similar. Called non-enzymatic glycation, this process occurs in tissues throughout the body, including in bone.

Just like an apple would turn brown, non-enzymatic glycation has a browning effect on proteins, creating tiny chemical bridges called crosslinks. Everyone develops crosslinks because everyone has some sugar in their bodies. Despite the fact that they are naturally formed, non-enzymatic crosslinks are not good for you.

They are harmful because they stiffen the proteins they are attached to, preventing them from flexing when subjected to the daily forces of simply walking around. This rigidity might sound like a good thing, but bones need a little flex or give to prevent micro-fractures from forming. Non-enzymatic crosslinks actually weaken bones by making them more brittle.

Usually, the body easily manages crosslinks by breaking them down and getting rid of them. But in the bones of people with Type 2 diabetes, it is a different story. Research from our lab and others have identified two troubling factors.

The first is that people with Type 2 diabetes have high sugar levels in their body. Because sugar is the fuel for the chemical reaction that forms crosslinks, we think there are more crosslinks inside diabetic bone than in normal healthy bone. My colleagues and I believe the accumulation of these crosslinks may be one reason diabetics have more fragile bones.

The second factor is that people with Type 2 diabetes have a low level of bone remodeling, which means their ability to clean out crosslinks is reduced. We think this contributes further to the already high number of crosslinks in diabetic bone.

Crosslinks have been studied in other organs. In diabetics, they have been found to contribute to complications such as vascular damage, kidney damage, and poor eye health. Studying crosslinks in bones is a relatively young field of study in general and even newer in diabetic bone.

Our team of biomedical engineers, mechanical engineers, civil engineers, chemists and medical doctors investigates crosslinks and micro-fractures by using diabetic bone from patients and cadavers.

In one study, we recruited diabetic patients who were undergoing hip replacement therapy and collected the hip bone specimens discarded during surgery for study. We found that the hard, dense bone that forms the outer shell of bones tended to have more crosslinks and weaker mechanical properties in diabetics than in nondiabetics.

We are also simulating high sugar levels in cadaver bone. Although cadaver bone is no longer living, the protein structure is still intact. When we incubate these bone samples in sugar solutions, the sugars can still react with the amino acids in the bone proteins to produce crosslinks. Recently, we used this technique to show that bone samples exposed to high-sugar environments produced more crosslinks, were weaker, and were more likely to develop micro-fractures.

My colleagues and I are currently working to measure different types of crosslinks and plan to look more closely at how and where micro-fractures form in bone. We are hoping to be able to predict how fractures might occur in patients. Additionally, were testing different compounds that might break down bone crosslinks or prevent them from forming in the first place, in hopes that our work will contribute to future treatments and better medical care for diabetic patients.

[Insight, in your inbox each day. You can get it with The Conversations email newsletter.]

See original here:
Diabetics break bones easily new research is figuring out why their bones are so fragile - The Conversation US

Internet of Things for Diabetes Market Research Report released by Research N Reports is a tool to inform businesses on histories, current trends and ample research to navigate through its complexities. Effective business strategies of the leading key players and startups have been explained in detail. The Internet of Things for Diabetes Market is expected to reach at a huge CAGR during the forecast period.

The research report details the classification of the Internet of Things for Diabetes Market. The Internet of Things for Diabetes Market is divided into several segments based on materials, types, applications, and end-users. The report also includes a geographic analysis of the global market. The vital information mentioned in the research report will help to predict the future of the global market.

For Sample Copy of this report: https://www.researchnreports.com/request_sample.php?id=166628

The report delivers a comprehensive overview of the crucial elements of the Market and elements such as drivers, restraints, current trends of the past and present times, supervisory scenario, and technological growth. A thorough analysis of these elements has been accepted for defining the future growth prospects of the global Internet of Things for DiabetesMarket.

Key Players:

Alien Technology, Ascensia Diabetes Care Holdings AG, Johnson & Johnson, Telcare, Inc., WellDoc, Inc., Proteus Digital Health, Inc., Diabetizer Ltd. & Co. KG, GlySens, Inc., Entra Health Systems LLC, and Dexcom, Inc.

This statistical surveying research report on the Internet of Things for Diabetes is an all-inclusive study of the business sectors latest outlines, industry growth drivers, and inadequacies. It gives market forecasts for the coming years. It contains an examination of the latest progressions in technology, Porters five force analysis and dynamic profiles of exclusive industry competitors. The report besides conveys an investigation of trivial and full-scale factors prosecuting for the new candidates in the market and the ones currently in the market.

Ask for Discount on this Report: https://www.researchnreports.com/ask_for_discount.php?id=789606

Reasons for Buying this Report:

Across the globe, several regions like North America, Latin America, Asia-Pacific, Europe, and Africa have been studied on the basis of sale and profit margin. Some significant key players have been profiled to get informative data to make informed decisions in the businesses. It makes use of info graphics, graphs, charts, tables, and pictures. For an effective and accurate business outlook, the report on the global Internet of Things for Diabetes Market examined details of the changing trends adopted by the top level companies.

Get Complete Report@ https://www.researchnreports.com/enquiry_before_buying.php?id=166628

About Us:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut throat Global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently we keep evolving as an all-rounder provider of viable information under one roof.

Contact:

Sunny Denis

Research N Reports

10916, Gold Point Dr,

Houston, TX, Pin 77064,

+1 510-402-1213,

sales@researchnreports.com

https://www.researchnreports.com

Diabetes Insulin Pumps Global Market 2020 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers noteworthy data regarding industrys growth parameters, the current state

Read this article:
Global Internet of Things for Diabetes Market Insights 2020 Demand Growing Rapidly with Major Player- Alien Technology, Ascensia Diabetes Care...

Zimmer MedizinSysteme

Moreover, the Millimeter Wave Diabetes Treatment Devices report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Millimeter Wave Diabetes Treatment Devices market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Millimeter Wave Diabetes Treatment Devices market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=146352&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Millimeter Wave Diabetes Treatment Devices Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Millimeter Wave Diabetes Treatment Devices Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Millimeter Wave Diabetes Treatment Devices Market, By Deployment Model

5.1 Overview

6 Millimeter Wave Diabetes Treatment Devices Market, By Solution

6.1 Overview

7 Millimeter Wave Diabetes Treatment Devices Market, By Vertical

7.1 Overview

8 Millimeter Wave Diabetes Treatment Devices Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Millimeter Wave Diabetes Treatment Devices Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=146352&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Millimeter Wave Diabetes Treatment Devices Market Size, Millimeter Wave Diabetes Treatment Devices Market Trends, Millimeter Wave Diabetes Treatment Devices Market Growth, Millimeter Wave Diabetes Treatment Devices Market Forecast, Millimeter Wave Diabetes Treatment Devices Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Digital Out Of Home Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Iris Recognition Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See more here:
Millimeter Wave Diabetes Treatment Devices Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Diabetes and obesity may have a significant effect on the severity of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19). Furthermore, COVID-19 may affect treatment for patients with type 2 diabetes and necessitates re-evaluation of medications, according to a review published in Endocrine Reviews.

It is well known that diabetes is associated with increased risk for various infections and related adverse outcomes and previous studies have shown that SARS-CoV-2 hospitalizations are more common in patients with diabetes and obesity.

Pulmonary cells may express key proteins that facilitate the entry of coronavirus into cells, including angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP-4), which are known to have pleiotropic metabolic activities directly contributing to the physiologic and pharmacologic control of cardiovascular and glucose homeostasis. Transmembrane protease serine 2 (TMPRSS2), a serine protease that is highly expressed within the lung and gastrointestinal tissues, is another potential key protein for coronarvirus entry and inflammation.

When treating patients with type 2 diabetes who are infected with coronavirus, several factors should be noted:

Metformin, which exerts anti-inflammatory actions, was previously found to be useful in patients with stable hepatitis or HIV infections, but limited data are available on its effect in patients with COVID-19. It should be used with caution in unstable hospitalized patients and discontinued in the presence of sepsis or severe hepatic or renal dysfunction.

Inhibitors of DPP-4 are widely used to treat patients with type 2 diabetes, leading to 50% to 95% inhibition of DPP-4 activity over a 24-hour period. There are limited data on the effect of these medications on clinical outcomes in patients with COVID-19. Dose reduction should be considered in those with significant volume depletion or systemic sepsis and renal dysfunction. Previous studies have shown that these medications do not have a major effect on immune function or inflammatory cytokines in patients with or without type 2 diabetes and are not associated with increased risk for infections. According to several studies and a meta-analysis of multiple DPP-4 inhibitors to examine the safety of saxagliptin, alogliptin, sitagliptin, and linagliptin in humans with type 2 diabetes, these medications have no clinically relevant safety concerns related to infections, immune disorders, or inflammatory disorders.

Glucagon-like peptide-1 (GLP-1) receptor agonists, which have anti-inflammatory properties, have been shown to attenuate pulmonary inflammation, reduce cytokine production, preserve lung function, and reduce lung injury in animal models with experimental lung injury. GLP-1 receptor agonists have been investigated in the perioperative period and in the intensive care unit and have generally been proven safe and effective for blood glucose control. However, limited data are available on the safety of these agents for critically ill patients or patients with SARS-CoV-2 infection and exenatide-based formulations should be stopped in those with kidney dysfunction.

Insulin treatment has been the most extensively used treatment in patients with acute infection and in critically ill patients. In addition to glucose control, insulin was found to have anti-inflammatory properties and reduce inflammatory markers in hospitalized patients with critical illness. However, limited data are available on the potential benefits or risks of insulin in patients with acute SARS-CoV-2 infection.

Sulfonylureas, which increase the risk for hypoglycemia, should be avoided in patients with severe illness. In a similar fashion, because of the increased risk for volume depletion and euglycemic ketoacidosis, sodium-glucose cotransporter 2 (SGLT2) inhibitors should be routinely discontinued in unstable patients with severe SARS-CoV-2 upon admission.

Of note, patients with type 1 diabetes are not considered to be at an increased risk for SARS-CoV-2 infection. However, the interruption of normal daily activities and limited access to healthcare providers may have a significant effect on disease management and some individuals with complications should still be seen in diabetes clinics for assessment and appropriate therapy.

The rapid flow of new clinical information stemming from the SARS-CoV-2 epidemic requires ongoing scrutiny to understand the prudent use, risks and benefits of individual glucose-lowering agents and related medications commonly used in subjects with diabetes at risk of, or hospitalized with coronavirus-related infections, wrote Daniel J. Drucker, MD, professor of medicine and senior investigator at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, Ontario, who authored the review.

Reference

Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications [published online April 15, 2020]. Endocr Rev. doi:10.1210/endrev/bnaa011

This article originally appeared on Endocrinology Advisor

More:
Effects of COVID-19 on Treatment Choice for Type 2 Diabetes - Medical Bag

Studies show that COVID-19, cancer, Alzheimer's, heart disease, and diabetes have one common factor and root: inflammation. This is now a key factor in many other diseases that have been emerging recently, and it's a process that everybody needs to understand and study more if we want to try and reduce risks.

This root has been identified as a major problem in COVID-19 cases, which explains why older people and those who have lifestyle diseases are most at high risk.

(Photo : Screenshot from: Pexels Official Website)

Read Also: COVID-19 UPDATE: Stem Cell Clinics Offer Unproven "Immunity Booster" for COVID-19 Without Any Proof It Works, You Have Been Warned

For scientists and medical experts, inflammation is a huge clue to what lies beneath the huge number of coronavirus deaths in the United Kingdom now total 32,065 compared to Spain's 26,744, and Italy's 30,560. These numbers reflect the seriousness of the underlying chronic disease.

However, doctors are hopeful that knowledge gained from studying COVID-19 will help us further understand inflammatory processes and suggest different ways to approach this pandemic that has plagued millions of people all over the world.

When we talk about inflammation, this is a sign of the human body's natural response to an infection. When the immune system is mobilized, activity by the defensive cells causes by-products like skin redness and heat or even a fever to occur when the entire system is involved.

Read Also: COVID-19 U.K. Update: People Who Have Low Paying Jobs Are More Likely To Get Infected And Have Died More From COVID-19, Analysis States

However, it should also be noted that obesity and chronic disease can cause inflammation as well.

According to Daily Mail, "Overweight people - almost two out of three Britons fall into this group - have been shown to have higher levels of inflammatory messenger molecules called cytokines, which interfere with and damage normal cell functions. A major research review, published in 2016 by the American Society for Nutrition, concluded that obesity and the health problems associated with it - such as high blood pressure, raised blood sugar levels and tummy fat - have a 'substantial impact' on the health of the immune system and defense against disease."

Research that was published last week by an Oxford University team that identified and analyzed health records from more than 17.4 million people, has calculated that the most severely obese and overweight people are three times more likely to suffer and die of coronavirus.

The body's immune system has a total of two lines of defense, innate immunity, which includes cell types that are on the lookout for foreign fungus, bacteria, and viruses. The second line is something that is more unique to each person that has developed over time to identify and destroy any kind of invader that has tried to invade our body in the past.

"The problem is that innate immunity starts to deteriorate from the age of about 50 and goes into a steep decline from 70. Adaptive immunity also starts to fail, with specialist antibody cells 'forgetting' to recognize the invaders they are meant to protect against. This malfunction occurs even in otherwise healthy older people, and the immune system tries to compensate for the deficit by over-producing cytokines, which buzz about looking for trouble - but in doing so cause inflammation," The Daily Mail added.

A spokesperson for the World Cancer Research Fund, Kate Allen, said that having a healthy weight is very critical in trying to reduce risks from cancer.

Fifteen of the most common cancers, which include colon, prostate, and breast are more common in people who are overweight caused by the inflammation.

Read Also: After Making a "Low Risk" Contact with COVID-19 Tests Positive White House Staffer, Dr. Anthony Fauci Will Begin Modified Quarantine

2018 TECHTIMES.com All rights reserved. Do not reproduce without permission.

More:
Doctors Say Inflammation Might be the Root of COVID-19 Along with Other Diseases Such as Cancer and Dementia - Tech Times

CALGARY, Alberta, May 11, 2020 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the Company or Voyageur) is pleased to announce it has signed an LOI with an established international mining company (the Counterparty) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from large natural-occurring fullerene resources.

The technology to extract C-60 from natural fullerene deposits is ground-breaking and a first in this industry. Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed, states Brent Willis, CEO of Voyageur Pharmaceuticals.

The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale, continues Brent Willis.

The API, C-60, is a natural, highly effective super antioxidant, like more common antioxidants (Vitamin C, Vitamin A and Selenium). It scavenges toxic free radicals but it stands out as a notable anti-aging innovation because it selectively scavenges the reactive oxygen species that do the most damage to humans as opposed to just working by osmosis like a normal antioxidant. The anti-aging properties are exciting, as studies in animals have shown the potential to significantly extend life span and to slow the aging process.

Voyageur has begun work on its first C-60 product, C-60X, an immune system booster, natural health product, for daily consumption. Voyageur is creating a C-60 R&D Therapeutics division that will be focused on developing natural health products and drugs. For early cash flow, Voyageur will utilize our Calgary-based manufacturing partners for natural health product sales.

Highlights of C-60 Medical Applications

"Thedifficulty inprocessingof fullerenes has presented a major problem in the search for medicinal applications. This is the breakthrough thatour partner hasrecentlyovercome. The patent-pending technology that can recover economic & high volumes of C-60 from natural fullerene mineral ores is a game changer. This opens the door for Voyageur to become the only company to have the capability to develop and mass produce C-60 based drugs and natural health products at a low cost & high volume, says Brent Willis.

Voyageur plans to develop low cost C-60 radiographic contrast drugs, which encapsulate iodine, gadolinium, and other potential molecules. By utilizing C-60, we may be able to enhance the performance and create the safest radiographic contrast media in the marketplace. Studies have shown that MRI C-60 gadolinium contrast media has a gain of a 500-fold sensitivity on intravital MR Contrast Agents.

Essentially, a carbon-60 molecule is comprised of 60 carbon atoms which are arranged in a unique shape that can be thought of as a 'carbon cage' (like a soccer ball). This sphere makes it possible to be a carrier of other molecules creating a protective shield, allowing C-60 to be an excellent drug delivery vehicle in radiology and healthcare.

This drug delivery system is quite unique to the pharmaceutical industry and our company is proud to begin the innovative steps to develop unique new delivery systems, states Brent Willis.

It has long been known that effective delivery systems are of paramount importance in promoting drug efficacy. This is not only a major milestone for our Company, but potentially a major breakthrough for the entire healthcare industry, continues Willis.The significance of the technological breakthrough, to extract natural fullerene from rock, may well pave the way for a low-cost evolution in the carbon-based health care market. Voyageur is the first company to begin to break down the barrier to market. The C-60 therapeutics division will enhance our Companys ability to become more competitive in the radiographic contrast market and become a leader in the C-60 drug & natural health sector. Fullerene is a gateway for Voyageur to become a leader in a new and exciting carbon medicine field. We will continue to build our From The Earth To The Bottle strategy, to become a fully-integrated competitive force in the API mineral based pharmaceutical industry.

The signed LOI for supply exclusivity will allow Voyageur to produce low cost & high-volume natural carbon-60 API for the pharmaceutical industry. This would allow Voyageur to be fully integrated in the C-60 market and become the only low-cost producer of fullerene based health care products. Voyageur is adding C-60 to its portfolio of active pharmaceutical ingredients (API) minerals for use in the radiographic contrast media markets. There are multiple applications for Fullerene based nano medicines in the healthcare industry, which Voyageur will further research and develop.

Due to confidentiality and pending patents, Voyageur cannot disclose at this time, the identity of the Counterparty.

About Voyageur

Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium, iodine radio-contrast products and fullerene-based pharmaceutical products.

Voyageurs goal is to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing.

Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, including interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radio-contrast medical field, by controlling all primary input costs under the motto of:

"From the Earth to the Bottle"

For Further Media Information or to set up an interview, please contact:

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain statements or disclosures relating to the Company that are based on the expectations of its management as well as assumptions made by and information currently available to the Company which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results, or developments that the Companyanticipates may or will occur in the future (in whole or in part) should be considered forward-looking statement and undue reliance should not be placed on any such statements. In some cases, forward-looking statements can be identified by the use of the words "will", "intends", believes, expects, forecasts, "anticipates", "plans" and similar expressions.

In particular, but without limiting the foregoing, this news release contains forward-looking statements pertaining to the following, the certainty of the disclosed LOI being made into a formal binding agreement; the ability of Voyageur to integrate fullerene into marketable pharmaceutical and healthcare markets; the feasibility and expectation of the Company to bring into production those mining assets it has an interest in; the experience of management and directors of Voyageur and its pharmaceutical manufacturingpartners to execute on its business plan and that of its joint venture company; the economics and risks associated with its business plan; future operations and strategies for development, sales and distribution of mineral and pharmaceutical product;; the Companys ability to successfully penetrate either domestic or foreign pharmaceutical markets; the amount, quality and cost of supply of active pharmaceutical ingredients for potential pharmaceutical products; the ability for Voyageur to meet its joint venture obligations; anticipated registrations with Health Canada or similar foreign bodies for various pharmaceutical products the Company plans to develop, produce and sell; and the ability of the Company to attract investment capital to fund operations and capital expenditures.

The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Source Information:

https://www.ncbi.nlm.nih.gov/pubmed/23785493/ https://phys.org/news/2019-09-fullerene-compounds-virus-infections-hiv.html, https://c60-france.com/media_upload/C60-Fullerene-nano-particles-Inhibit-HIV-Replication.pdf https://www.sesres.com/carbon-60-c60-powder/#buy_c60 https://www.sciencedirect.com/science/article/pii/S0142961212003237https://www.hindawi.com/journals/jnm/2015/565638/https://en.wikipedia.org/wiki/Fullerene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880842/ https://www.sciencedirect.com/science/article/pii/S0142961212003237 Mitsubishi https://www.azonano.com/article.aspx?ArticleID=47 https://pubs.acs.org/doi/full/10.1021/es801869m https://phys.org/news/2020-03-scientists-water-soluble-fullerene-compounds-medicine.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676811/https://pubs.acs.org/doi/10.1021/acsanm.9b01698

Continued here:
Voyageur Secures Exclusive Rights To One Of The Worlds Rarest Pharmaceutical Minerals, Creating A New Era In Carbon Based Drug Development -...

May 11, 2020 David Graves, an internationally-known chemical engineer, has been named to lead a new research enterprise that will explore plasma applications in nanotechnology for everything from semiconductor manufacturing to the next generation of super-fast quantum computers.

Graves, a professor at the University of California, Berkeley, since 1986, is an expert in plasma applications in semiconductor manufacturing. He will become the Princeton Plasma Physics Laboratorys (PPPL) first associate laboratory director for Low-Temperature Plasma Surface Interactions, effective June 1. He will likely begin his new position from his home in Lafayette, California, in the East Bay region of San Francisco.

He will lead a collaborative research effort to not only understand and measure how plasma is used in the manufacture of computer chips, but also to explore how plasma could be used to help fabricate powerful quantum computing devices over the next decade.

This is the apex of our thrust into becoming a multipurpose lab, said Steve Cowley, PPPL director, who recruited Graves. Working with Princeton University, and with industry and the U.S. Department of Energy (DOE), we are going to make a big push to do research that will help us understand how you can manufacture at the scale of a nanometer. A nanometer, one-billionth of a meter, is about ten thousand times less than the width of a human hair.

The new initiative will draw on PPPLs expertise in low temperature plasmas, diagnostics, and modeling. At the same time, it will work closely with plasma semiconductor equipment industries and will collaborate with Princeton University experts in various departments, including chemical and biological engineering, electrical engineering, materials science, and physics. In particular, collaborations with PRISM (the Princeton Institute for the Science and Technology of Materials) are planned, Cowley said. I want to see us more tightly bound to the University in some areas because that way we get cross-fertilization, he said.

Graves will also have an appointment as professor in the Princeton University Department of Chemical and Biological Engineering, starting July 1. He is retiring from his position at Berkeley at the end of this semester. He is currently writing a book (Plasma Biology) on plasma applications in biology and medicine. He said he changed his retirement plans to take the position at PPPL and Princeton University. This seemed like a great opportunity, Graves said. Theres a lot we can do at a national laboratory where theres bigger scale, world-class colleagues, powerful computers and other world-class facilities.

Exciting new direction for the Lab

Graves is already working with Jon Menard, PPPL deputy director for research, on the strategic plan for the new research initiative over the next five years. Its a really exciting new direction for the Lab that will build upon our unique expertise in diagnosing and simulating low-temperature plasmas, Menard said. It also brings us much closer to the university and industry, which is great for everyone.

The staff will grow over the next five years and PPPL is recruiting for an expert in nano-fabrication and quantum devices. The first planned research would use converted PPPL laboratory space fitted with equipment provided by industry. Subsequent work would use laboratory space at PRISM on Princeton Universitys campus. In the longer term, researchers in the growing group would have brand new laboratory and office space as a central part the Princeton Plasma Innovation Center (PPIC), a new building planned at PPPL.

Physicists Yevgeny Raitses, principal investigator for the Princeton Collaborative Low Temperature Plasma Research Facility (PCRF) and head of the Laboratory for Plasma Nanosynthesis, and Igor Kavanovich, co-principal investigator of PCRF, are both internationally-known experts in low temperature plasmas who have forged recent partnerships between PPPL and various industry partners. The new initiative builds on their work, Cowley said.

A priority research area

Research aimed at developing quantum information science (QIS) is a priority for the DOE. Quantum computers could be very powerful in solving complex scientific problems, including simulating quantum behavior in material or chemical systems. QIS could also have applications in quantum communication, especially in encryption, and quantum sensing. It could potentially have an impact in areas such as national security. A key question is whether plasma-based fabrication tools commonly used today will play a role in fabricating quantum devices in the future, Menard said. There are huge implications in that area, Menard said. We want to be part of that.

Graves is an expert on applying molecular dynamics simulations to low temperature plasma-surface interactions. These simulations are used to understand how plasma-generated ions, atoms and molecules interact with various surfaces. He has extensive research experience in academia and industry in plasma-related semiconductor manufacturing. That expertise will be useful for understanding how to make very fine structures and circuits at the nanometer, sub-nanometer and even atom-by-atom level, Menard said. Davids going to bring a lot of modeling and fundamental understanding to that process. That, paired with our expertise and measurement capabilities, should make us unique in the U.S. in terms of what we can do in this area.

Graves was born in Daytona Beach, Florida, and moved a lot as a child because his father was in the U.S. Air Force. He lived in Homestead, Florida; near Kansas City, Missouri; and in North Bay Ontario; and finished high school near Phoenix, Arizona.

Graves received bachelors and masters degrees in chemical engineering from the University of Arizona and went on to pursue a doctoral degree in the subject, graduating with a Ph.D. from the University of Minnesota in 1986. He is a fellow of the Institute of Physics and the American Vacuum Society. He is the author or co-author of more than 280 peer-reviewed publications. During his long career at Berkeley, he has supervised 30 Ph.D. students and 26 post-doctoral students, many of whom are now in leadership positions in industry and academia.

A leader since the 1990s

Graves has been a leader in the use of plasma in the semiconductor industry since the 1990s. In 1996, he co-chaired a National Research Council (NRC) workshop and co-edited the NRCs Database Needs for Modeling and Simulation of Plasma Processing. In 2008, he performed a similar role for a DOE workshop on low-temperature plasmas applications resulting in the report Low Temperature Plasma Science Challenges for the Next Decade.

Graves is an admitted Francophile who speaks (near) fluent French and has spent long stretches of time in France as a researcher. He was named Matre de Recherche (master of research) at the cole Polytechnic in Palaiseau, France, in 2006. He was an invited researcher at the University of Perpignan in 2010 and received a chaire dexcellence from the Nanoscience Foundation in Grenoble, France, to study plasma-graphene interactions.

He has received numerous honors during his career. He was appointed the first Lam Research Distinguished Chair in Semiconductor Processing at Berkeley for 2011-2016. More recently, he received the Will Allis Prize in Ionized Gas from the American Physical Society in 2014 and the 2017 Nishizawa Award, associated with the Dry Process Symposium in Japan. In 2019, he was appointed foreign expert at Huazhong University of Science and Technology in Wuhan, China. He served as the first senior editor of IEEE Transactions on Radiation and Plasma Medical Science.

Graves has been married for 35 years to Sue Graves, who recently retired from the City of Lafayette, where she worked in the school bus program. The couple has three adult children. Graves enjoys bicycling and yoga and the couple loves to travel. They also enjoy hiking, visiting museums, listening to jazz music, and going to the theater.

About PPPL

PPPL, on Princeton Universitys Forrestal Campus in Plainsboro, N.J., is devoted to creating new knowledge about the physics of plasmas ultra-hot, charged gases and to developing practical solutions for the creation of fusion energy. The Laboratory is managed by the University for the U.S. Department of Energys Office of Science, which is the largest single supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visitscience.energy.gov(link is external).

Source: Jeanne Jackson DeVoe, PPPL

See the original post here:
David Graves to Head New Research at PPPL for Plasma Applications in Industry and Quantum Information Science - HPCwire

The cannabis market is boomingnot just across the United States, but all over the world. In domino fashion, stigmas are falling and people are embracing a new perspective on cannabis. Not long ago, the war on cannabis was in full throttle. Now, old-school growers and opportunistic entrepreneurs have stepped forward to claim a piece of the proverbial pie.

Its important to examine data for how states fare after launching a legalized cannabis market. Pre-existing cannabis markets, like in Colorado and California, will exhibit different trends over time than brand-new markets like Oklahoma. For instance, the Washington state market grew 100 percent from 2015 to 2016. The following year, the rate declined to about 33 percent. Going into 2018, the growth estimate was about 10 percent, according to Headset. Its easy to see the trend: an initial explosion cools down over time. Who is still standing once growth plateaus? Thats the important question.

Cannabis legalization presents a massive opportunity, so its no surprise big capital and investment is rolling in across borders and state lines. Multi-state operators (MSOs) are growing in size. Take Curaleaf, for example, which plans to operate seventy-one dispensaries in fifteen states by the end of 2020. This is a new kind of cannabis business. They scale by acquiring licenses and operators. Market share can be bought and sold like any other commodity.

When it comes to growing and feeding the plants, no two cultivators offer the same philosophy, feeding recipe, or training protocol.

Depending on where you are, different market forces will work for or against you. New states like Oklahoma have comparatively lax regulations that have inspired hobby growers and opportunists to stake a claim. Then there are states like Illinois, in which a publicly traded real estate firm is acquiring three of the seven total cultivation licenses.

In maturing markets, recent data show wholesale pricing for cannabis is increasing. Last year reversed a downward trend in pricing over the previous four years. But in any market, new or mature, overproduction and saturation can occur.

The days of easy sales at premium prices are getting farther away from us. So, how do growers face the changing tides and establish a sustainable cultivation business?

At one time, being a skilled grower was enough to command high prices and constant demand for product. Now, with increasing competition, MSOs, and price volatility, growers are wondering how to ensure their product sells and how to stabilize margins to ensure longevity for their business.

In general, indoor-grown product will command a higher price solely because of the cost of inputs and higher THC levels. But some outdoor growers can command top-shelf pricing for their flower. How do they do it?

Memorable branding

Beyond the commodity-versus-premium comparison lies another variable: branding. We wont name names, but crappy product can and does command a high price if its wrapped in premium branding and packaging. Its all about the first impression.

Good branding coupled with low-quality product may not prove successful over the long term, though. As customers mature in their preferences, they learn which brands offer the best value. If product smells good, tastes good, and feels good, it always will command a good price, special packaging or not. With so many choices on the shelf, why would a customer go back to the same over-priced brand when they can get a much better smoke from another?

Heres a tip: invest in a good designer or design agency to lead the branding process. Dont try to wing it yourself or hire someone from 99designs. Take the time to develop your brand positioning and messaging. Even if consumers love your product so much they dont care what the packaging looks like, the package needs to be memorable so theyll be able to find your product the next time they want to buy.

Your favorite brands, as simple as their marketing materials may seem, all have a very strong brand framework. Take the time and make the investment to create one of your own.

Science as art

Some cultivators are truly passionate about mastering the art and science of growing. Factors like aroma, flavor, and effects are achieved through breeding efforts in search of the perfect combination of genetic traits. When it comes to growing and feeding the plants, no two cultivators offer the same philosophy, feeding recipe, or training protocol. There are a million ways to create great weed.

As customers mature in their preferences, they learn which brands offer the best value.

The pursuit of next-level cannabis is responsible for decades of crossbreeding in Californias Emerald Trianglewhere cannabis breeding got its startand beyond. In fact, cannabis may be one of the most bred plants in the world.

The absence of standardized growing methods and consumers differing preferences for strains and effects provide growers huge opportunities to define their style and product offering among an ever-growing field of competitors.

Here are some ideas to get you thinking about how you might position yourself to stand out in the crowd:

Are your genetics unique? What is your best strain and what makes it so? (Run that full terpene analysis!)

Do you use full automation or give each plant your undivided attention?

Do you use customized formulas? Think schedule, feeding, topping or super-cropping, and curing methods.

Whats your personal story? You can build a powerful brand based on who you are, where you come from, and why you do what you do.

Unique partnerships

Another way to gain recognition and brand awareness in a competitive space is to leverage others networks. Together, two brands cast a bigger shadow than either does on its own.

Take for example the hip brand Space Coyote. The company infuses its joints with high-quality cold water hash from the respected Humboldt brand Nasha. Space Coyote was a startup in 2019, but its partnership with Nasha gave the company a bit of authority right from the start, which makes a big difference for a nascent brand.

Now, Space Coyote lends authority back to Nasha. As Space Coyotes pre-rolls grow in popularity, Nashas reputation increases as well. The partnership allows two complimentary brands to up each others games.

Think co-branding on packaging, or co-sponsor an event for the cannabis community or consumers. Cross-promote each other through social media, in email, and on websites. Good partnerships boost brand awareness.

Be sure to pick a trusted partner. Your reputation will depend on theirs. If they make a blunder and get bad press, your name is on the line, too.

Manage profit margins

However your pricing strategy may look, keeping a close eye on margins and profitability is crucial to sustained success. Large grows with hefty investment can afford to work with slim to no margins. For them, market share can be more important than raw profit.

Other businesses survive from harvest to harvest. Healthy margins are extremely important. Being able to reinvest in the business should be every growers goal.

Pay attention to margins ahead of when everyone else starts to squeeze. Increase prices, lower costs, or rely on an economy of scale, but stay one step ahead of the competition.

Increase efficiency

Efficiency comes in many forms: labor, cost of inputs, equipment choices, energy savings, even genetics. One grower made huge efficiency improvements by examining data about time and task management, environmental conditions, and plant batch analytics, then using the trends they noticed to modify their operations.

Hand-watering, for example, was incredibly expensive: Watering alone accounted for 30 percent of the cultivators labor costs. Initially, they implemented more efficient watering practices, but that made only a small difference in man-hours. After crunching more numbers, they invested in an auto-watering system. The investment paid for itself in two months.

The point is, there are efficiencies to be gained everywhere you look in your organization. Data can play into your competitive edge. This is especially true for those with multiple grow rooms or facilities.

Data is power

Software that collects and analyzes data in order to help businesses make informed decisions should be on everyones radar, as it can provide demonstrable competitive advantage. Most third-party software systems handle compliance by integrating with track-and-trace systems like Metrc or BioTrack. Cultivators probably also want built-in utilities for tracking employee productivity and providing performance analytics.

While all-in-one tools seem like a good idea, stacking purpose-built software can have a greater impact. Adding cultivation-focused software can address inefficiencies and improve production quality and yieldsespecially in the cannabis industry, where there are unique scenarios and data points many general-purpose software tools just dont address.

The more accurate and more comprehensive your data, the smarter your business decisions can be.

Ella Alpina is marketing manager at Trym, a farm management and compliance software company. Prior to Trym, she launched a licensed cannabis business in California and before that, founded and led a full-service marketing agency. She has worked in the cannabis space since 2014 and is passionate about the intersection of technology and cannabis.

Read the rest here:
The cannabis market is boomingnot just across the United States, but all over the world. In domino fashion, s - mg Cannabis Retailer

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung cancer and this type of mutation.

Tabrecta is the first therapy approved by the FDA specifically to treat NSCLC with mutations that lead to epithelial-mesenchymal transition (EMT), which is MET exon 14 skipping.

Tabrecta is approved for patients who are new to treatment and also those who have received previous therapies, regardless of prior treatment type.

Along with the drug approval, the FDA gave the green light to a companion diagnostic, the FoundationOne CDx assay, which can identify these mutations in patients.

In epithelialmesenchymal transition(EMT), the cells that line an organ lose their polarity and ability to adhere to other cells, giving them the ability to invade tissues and organs. MET exon 14 skipping means that a segment of RNA that should prompt the production of a specific protein stops sending those messages.

The spread of cancer consists of a sequential series of events and MET exon 14 skipping is recognized as a critical event in this process, the FDA stated in a press release about the approval. Mutations leading to MET exon 14 skipping are found in 3% to 4% of patients with lung cancer, the agency stated.

Lung cancer is increasingly being divided into multiple subsets of molecularly defined populations with drugs being developed to target these specific groups, said Dr. Richard Pazdur, director of the FDAs Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDAs Center for Drug Evaluation and Research, in the release.

Taken orally, Tabrecta works by blocking a key protein that drives metastatic NSCLC in these patients. The FDA approved it based on the results of a clinical trial involving patients with NSCLC who had mutations leading to MET exon 14 skipping; their tumors did not express the proteins EGFR or ALK.

The evaluated study population included 28 patients who had never undergone treatment for NSCLC and 69 previously treated patients. The overall response rate (ORR; the percentage of participants who experienced a prespecified amount of tumor shrinkage) for the 28 participants was 68%, with 4% having a complete response and 64% having a partial response.

The ORR for the 69 participants was 41%, with all having a partial response. Of the responding participants who had never undergone treatment for NSCLC, 47% had a duration of response lasting 12 months or longer compared with 32.1% of the responding participants who had been previously treated.

Common side effects for patients taking Tabrecta included swelling of the legs, nausea, fatigue, vomiting, shortness of breath and decreased appetite.

Tabrecta may cause serious side effects including scarring or inflammation of the lungs. It may also cause damage to liver cells or harm a developing fetus or newborn baby. Patients may be more sensitive to sunlight when they take Tabrecta and should take precautions to cover their skin and use sunscreen.

Tabrecta was approved under theFDAs accelerated approval, breakthrough designation and priority review programs, which provide for a quicker review of drugs that treat serious or life-threatening diseases and represent a meaningful advantage over existing treatments.

Continued approval for this indication may be contingent upon verification of these results in confirmatory clinical trials.

Check back for what you need to know regarding this approval.

See original here:
FDA Approves Tabrecta, the First Targeted Drug for Patients with Non-Small Cell Lung Cancer and MET exon 14 - Curetoday.com

Opthalmology Drugs and Devices MarketLatest Research Report 2020:

The Opthalmology Drugs and Devices report provides an independent information about the Opthalmology Drugs and Devices industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Opthalmology Drugs and Devices Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Opthalmology Drugs and Devices Market: Products in the Opthalmology Drugs and Devices classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Merck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch & Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson & Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

Opthalmology Drugs and Devices Market Report Covers the Following Segments:

Segment by Type:

DeviceDrug

Segment by Application:

HosptialClinicOthers

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Opthalmology Drugs and Devices Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Opthalmology Drugs and Devices Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Opthalmology Drugs and Devices Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Opthalmology Drugs and Devices Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Opthalmology Drugs and Devices Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Opthalmology Drugs and Devices Market.

Market Forecast:Here, the report offers a complete forecast of the global Opthalmology Drugs and Devices Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Report:

https://www.marketwatch.com/press-release/us-electric-thermostatic-valves-market-2020-industry-analysis-key-strategies-demand-size-share-and-regional-trends-by-forecast-to-2025-2020-04-07

https://www.marketwatch.com/press-release/us-bioactive-material-market-examines-analysis-by-latest-trends-growth-factors-key-players-and-forecasts-2020-2025-2020-04-07

Read more here:
COVID-19 pandemic Opthalmology Drugs and Devices Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty

Ming-Chen Sun,1,* Xiao-Ling Xu,1,* Xue-Fang Lou,2 Yong-Zhong Du1

1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Peoples Republic of China; 2School of Medicine, Zhejiang University City College, Hangzhou 310015, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yong-Zhong DuInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, Peoples Republic of ChinaTel +86-571-88208435Fax +86-571-88208439Email duyongzhong@zju.edu.cnXue-Fang LouSchool of Medicine, Zhejiang University City College, 51 Hu-Zhou Street, Hangzhou 310015, Peoples Republic of ChinaTel +86-571-88013011Fax +86-571-88018442Email louxf@zucc.edu.cn

Abstract: Vitiligo is a depigmentation disease that seriously affects the physical health, mental health and quality of life of a patient. Therapeutic aim at control immunoreaction by relieving oxidative stress. Unfortunately, the cuticle barrier function and lack of specific accumulation lead to unsatisfactory therapeutic outcomes and side effects. The introduction and innovation of nanotechnology offers inspiration and clues for the development of new strategies to treat vitiligo. However, not many studies have been done to interrogate how nanotechnology can be used for vitiligo treatment. In this review, we summarize and analyze recent studies involving nano-drug delivery systems for the treatment of vitiligo, with a special emphasis on liposomes, niosomes, nanohydrogel and nanoparticles. These studies made significant progress by either increasing drug loading efficiency or enhancing penetration. Based on these studies, there are three proposed principles for topical nano-drug delivery systems treatment of vitiligo including the promotion of transdermal penetration, enhancement of drug retention and facilitation of melanin regeneration. The presentation of these ideas may provide inspirations for the future development of topical drug delivery systems that will conquer vitiligo.

Keywords: vitiligo, nano-drug delivery system, transdermal penetration, liposomes, skin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

The rest is here:
Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press

Transportation restrictions and stringent government policies are causing a downturn in the growth scale of the Nanomedicine market amidst the COVID-19 (Coronavirus) lockdown period. Hence, analysts at Market Research Reports Search Engine (MRRSE) have collated a research study that provides an in-depth outlook on Coronavirus and how the novel virus can leave long-term effects in trade practices post lockdown period in the Nanomedicine market.

Why Choose MRRSE?

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

The report on the global Nanomedicine market published by MRRSE provides a clear understanding of the flight of the Nanomedicine market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Nanomedicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Nanomedicine market are analyzed in the report.

The study reveals that the global Nanomedicine market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Nanomedicine market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Key Takeaways of the Report:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/3117?source=atm

Nanomedicine Market Segmentation

The presented study throws light on the current and future prospects of the Nanomedicine market in various geographies such as:

The report highlights the product adoption pattern of various products in the Nanomedicine market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Go here to read the rest:
Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024...

Technology makes processes easier, faster, safer, and more efficient. Shouldnt it, therefore, also reduce costs?

This isnt always the case. Thats because researching and developing new technology can cost millions of dollars; add to that the cost of materials and production. By the time that technology is launched, billions may have been spent developing it.

New technology has brought immense benefits to the following four industries, but it hasnt necessarily lowered costs for consumers.

Medical technology is so innovative that doctors can now insert tiny robotics into the body to repair internal wounds or remove objects. This is a branch of medicine called nanomedicine. Nanomedicine uses nanosized (even smaller than microsized) carriers to transport drugs to specific cells or tumors in the body. This form of technology opens up a new way to treat cancer, for instance. Rather than subject the entire body to chemotherapy, nanotechnology can deliver chemotherapy drugs directly to the tumor.

These types of treatments, however, dont come cheap. In fact, healthcare costs in the United States continue to rise. In 2018, the U.S spent $3.6 trillion on healthcare, which works out to an average of $11,000 per person. This is projected to increase to $18,000 per person by 2028.

One of the main drivers of escalating healthcare costs is medical technology. According to a report by The Hastings Center, healthcare economists found that 40 percent to 50 percent of annual healthcare cost increases were linked to new medical technologies.

Sustainable energy has a positive impact on the environment. Solar- and wind-powered energy mean less reliance on harmful fossil fuels for energy production. Electric cars eliminate toxic fuel emissions.

But solar panels can be costly to install, and electric cars are often more expensive to buy than traditional cars. Electric vehicles can range in pricing from $31,915 for a Nissan Leaf to $70,875 for the Jaguar I-Pace.

The good news is these products pay for themselves over time with the savings on your electric and gas bills. In addition, buying an electric car or implementing energy-saving technology in your home can make you eligible for a rebate. States like California offer rebates of up to $500 when installing solar products and up to $7,000 when buying an electric vehicle.

Many of the aviation safety systems that are standard on planes today were born from past mistakes. When an airplane crashes, a thorough investigation is conducted. The lessons learned from a catastrophic disaster often lead to improved safety technology.

The aviation industry has made giant strides in technology to make flying safer, lower the cost of fuel, and find ways to reduce airplane emissions. Engineers are looking at ways to manufacture lighter engines and using 3D printing to design and produce lighter aircraft parts. Every part that becomes lighter, even brackets and hinges, helps decrease the planes overall weight and boost fuel efficiency.

In their quest to reduce their carbon footprint, aircraft manufacturers are following the example of the automotive industry and testing electric engines for airplanes. Theyre also testing biofuels, such as sugarcane and cooking oil. According to NASA, a 50/50 blend of jet fuel and biofuel can cut soot emissions by 50 percent. While this is great for the environment, flying a plane with biofuels costs more than traditional jet fuel.

Despite new technology and lower fuel costs, travelers are unlikely to see a drop in the cost of flights. And with the COVID-19 pandemic grounding planes across the globe, many airlines are likely to try to recoup losses by charging higher fares when travel resumes.

Car safety technology, like collision avoidance systems, blind-spot monitoring, automated braking, lane keep assist, and rear-view backup cameras have become standard on most new cars.

Despite the fact that the National Highway Traffic Safety Administration and the Insurance Institute for Highway Safety agree that safety tech in cars is effective in reducing car crashes, insurance companies havent lowered their rates on cars that feature them. The only car safety technologies that lower insurance rates are electronic stability control and telematics.

If car tech helps prevent accidents, why arent insurance rates lower? Insurance companies cite the following reasons:

Technology improves our lives in many ways, but it doesnt always lower costs. In some cases, it may even increase the cost of goods or services. The tradeoff is in what we gain from new technologies: more efficiency, better safety, time-saving convenience, and less damage to the environment.

Link:
The Benefits of Tech Even Those That Don't Cut Costs - The Tech Report

Endo International

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Healthcare Nanotechnology (Nanomedicine) market. A competition analysis is imperative in the Healthcare Nanotechnology (Nanomedicine) market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Healthcare Nanotechnology (Nanomedicine) across the world has been calculated through primary and secondary research. The Healthcare Nanotechnology (Nanomedicine) Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=NYH&utm_medium=888

Highlights of the Healthcare Nanotechnology (Nanomedicine) market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Healthcare Nanotechnology (Nanomedicine) market. Additionally, it includes a share of every segment of the Healthcare Nanotechnology (Nanomedicine) market, giving methodical information about types and applications of the market.

Key point summary of the Healthcare Nanotechnology (Nanomedicine) market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Healthcare Nanotechnology (Nanomedicine) market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Healthcare Nanotechnology (Nanomedicine) market

Chapter 2: Evaluating the leading manufacturers of the global Healthcare Nanotechnology (Nanomedicine) market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Healthcare Nanotechnology (Nanomedicine) market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Healthcare Nanotechnology (Nanomedicine) market describes Healthcare Nanotechnology (Nanomedicine) industry expansion game plan, the Healthcare Nanotechnology (Nanomedicine) industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Trends, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Offshore AUV and ROV Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Oil & Gas Analytics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

View original post here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

It is my opinion that over the next 5 to 10 years the delivery of medicine will change dramatically. The pharmacist of the future will become the pharmacist of the past. Many years ago, before the incredible sophistication of the pharmaceutical industry, many pharmacists compounded medications in their own facility.

I foresee a situation where a person will go to the doctor following a full assessment of their own genome. A treatment plan will be formulated based on the persons own genetic abnormalities and predispositions. Rather than taking a number of separate pharmaceutical pills and, for those so inclined, vitamin supplements, the doctor will administer a personalised prescription for the person. This will be taken to their pharmacist and, using nanotechnology, all of these therapies will be delivered within the one small pill, taken once daily.

The technology would be advanced to the point where each separate medication within the nano-pill would be released at the appropriate time into the circulation. We are well aware that computer technology power doubles every 18 months and the advances in nanotechnology appear to be mirroring this.

On a separate, but similar, note, the University of Pittsburgh has released recently in the Journal of Investigative Dermatology, a fingertip patch with 400 microneedles for vaccine delivery for live or attenuated vaccines.

The microneedles are made from three-dimensional sugar structures incorporated into what is known as a multicomponent dissolving microneedle array. Interestingly, this not only induces an antibody response but also improves the cellular response better than standard vaccines given via injection. It appears from the preliminary studies that this will induce a strong and long-lasting immunity. The researchers trialled this in mice administering a live adenovirus with encoded antigens and a specific immune stimulant to enhance the local immune response.

In the last few weeks, researchers at the University of Oxford in England have started a trial of a vaccine for the Coronavirus. It may be that, in the very near future, rather than the needle jab, we are using these micro patches instead for all vaccines.

Researchers from Harvard University in the USA are also working on a similar patch technology for the management of diabetes. The patch not only delivers insulin through the skin but also measures real-time blood sugar levels.

At present, the vast majority of insulin-dependent diabetics need to constantly prick their fingers to monitor blood sugar levels and then inject themselves on multiple occasions throughout the day. Again, over the next few years, the management of diabetes will be revolutionised by the use of these micro patches.

For many chronic conditions affecting millions of people, especially over the age of 50, the future of chronic medical management is very bright. When I started medical school in the 1970s, our medical and surgical therapies were modestly effective and I have seen a revolution in the management of chronic illnesses, such as cardiovascular disease and cancer, over the past 40 to 50 years.

With these extraordinary advances mentioned above, which are only a portion of what we will see over the next decade, the future of medicine is looking very bright indeed.

Visit link:
The future of medicine - Switzer Financial News

The market research study titled Global Nanomedicine Market Size, Status and Forecast 2020-2026 brings you the most recent and the most updated data on the market. The report provides extensively researched information about the global Nanomedicine market structure, valuates, and outlines its variable aspects and applications. The report comprehensively represents the context of current and future trends driving the profit matrix. The report contains computable information, qualitative information sets, and evaluation tools. The research highlights major market insights, challenges, current trends, and value chain analysis.

The study provides estimates on global Nanomedicine market share, market size, and regional topography along with statistics, diagrams and charts explaining the differing interesting framework of the industry landscape. Divided by product type, applications, industry verticals, and research regions, the report research document delivers an explanation of the perspectives and comprehensive market statistics. It further covers the pricing of the product, production and consumption volume, cost analysis, industry value, barriers and growth drivers, major market players, demand and supply ratio of the market, the growth rate of the market and forecast from 2020 to 2026. Top players are completely profiled in this report.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/28942/request-sample

The major manufacturers covered in this report: Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences,

Regional Analysis For Market:

North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa) are leading countries and provide data like market share (%), sales (volume), imports & exports by types and applications, analysis, production, consumption, and consumption forecast. Information about different regions helps the reader to understand the global Nanomedicine market better.

Product type coverage (market size & forecast, a major company of product type etc.):

Application coverage (market size & forecast, different demand market by region, main consumer profile etc.): Segmentation encompasses oncology, Infectious diseases, Cardiology, Orthopedics, Other

Moreover, the report has included the leading merchants in this global Nanomedicine market everywhere throughout the world. In this part, market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue are determined. Additionally, upstream raw materials and downstream demand studies are administered. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The report further incorporates speculation attainability investigation and venture return investigation.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanomedicine-market-size-status-and-forecast-2020-2026-28942.html

Some of The Points Explained in The TOC of Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post:
Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 - Jewish Life News